End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.13 USD | +0.64% |
|
+9.82% | -42.25% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 124.1 | 101.8 | - | - |
Enterprise Value (EV) 1 | 29.2 | -42.31 | -66.1 | 11.14 |
P/E ratio | -2.04 x | -1.88 x | -0.87 x | -0.64 x |
Yield | - | - | - | - |
Capitalization / Revenue | 62 x | - | - | - |
EV / Revenue | 14.6 x | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 22,896 | 31,914 | - | - |
Reference price 2 | 5.420 | 3.190 | 3.190 | 3.190 |
Announcement Date | 3/25/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -30.74 | -55.18 | -141.1 | -205.2 |
Operating Margin | - | -1,537% | - | - | - |
Earnings before Tax (EBT) 1 | - | -27.88 | -50.74 | -114.8 | -179.9 |
Net income 1 | -30.5 | -27.88 | -52.98 | -116.4 | -181.3 |
Net margin | - | -1,393.8% | - | - | - |
EPS 2 | -165.3 | -2.660 | -1.700 | -3.675 | -5.005 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -7.057 | -7.452 | -9.466 | -8.768 | -10.73 | -14.19 | -21.5 | -27.19 | -29.38 |
Operating Margin | - | -372.6% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.785 | -6.353 | -8.151 | -6.629 | -9.928 | -13.48 | -20.68 | -27.19 | -29.38 |
Net income 1 | -6.785 | -6.353 | -8.151 | -6.629 | -10.27 | -14.36 | -21.71 | -27.19 | -29.38 |
Net margin | - | -317.65% | - | - | - | - | - | - | - |
EPS 2 | -35.80 | -0.3500 | - | -0.2300 | -0.3340 | -0.4520 | -0.6760 | -0.9300 | -1.000 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/21/23 | 11/13/23 | 3/25/24 | 5/15/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | 94.9 | 144 | 168 | 90.7 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.25% | 102M | |
+18.09% | 45.01B | |
+45.43% | 40.96B | |
-8.38% | 38.62B | |
+34.66% | 32.6B | |
-8.34% | 27.49B | |
+16.10% | 27.17B | |
+49.73% | 14.61B | |
+36.71% | 12.95B | |
-6.60% | 11.36B |
- Stock Market
- Equities
- SGMT Stock
- Financials Sagimet Biosciences Inc.